CA2404060A1 - Methodes de traitement de la neoplasie avec des adenovirus specifiques des cellules cibles associes a la chimiotherapie et a la radiotherapie - Google Patents

Methodes de traitement de la neoplasie avec des adenovirus specifiques des cellules cibles associes a la chimiotherapie et a la radiotherapie Download PDF

Info

Publication number
CA2404060A1
CA2404060A1 CA002404060A CA2404060A CA2404060A1 CA 2404060 A1 CA2404060 A1 CA 2404060A1 CA 002404060 A CA002404060 A CA 002404060A CA 2404060 A CA2404060 A CA 2404060A CA 2404060 A1 CA2404060 A1 CA 2404060A1
Authority
CA
Canada
Prior art keywords
specific
tre
cell
cells
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002404060A
Other languages
English (en)
Inventor
De-Chao Yu
Yu Chen
Daniel R. Henderson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cell Genesys Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2404060A1 publication Critical patent/CA2404060A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Cette invention concerne des méthodes de traitement de la néoplasie avec des vecteurs adénoviraux spécifiques des cellules cibles capables de réplication, associés à la chimiothérapie ou à la radiothérapie, ou leurs combinaisons. Les vecteurs adénoviraux sont spécifiques des cellules cibles pour le type particulier de néoplasie pour lequel le traitement est nécessaire, et la chimiothérapie et/ou la radiothérapie combinées fournissent un traitement synergique relativement aux thérapies adénovirales existantes ou aux chimiothérapies et radiothérapies classiques.
CA002404060A 2000-03-24 2001-03-21 Methodes de traitement de la neoplasie avec des adenovirus specifiques des cellules cibles associes a la chimiotherapie et a la radiotherapie Abandoned CA2404060A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19201500P 2000-03-24 2000-03-24
US60/192,015 2000-03-24
PCT/US2001/009042 WO2001072341A2 (fr) 2000-03-24 2001-03-21 Methodes de traitement de la neoplasie avec des adenovirus specifiques des cellules cibles associes a la chimiotherapie et a la radiotherapie

Publications (1)

Publication Number Publication Date
CA2404060A1 true CA2404060A1 (fr) 2001-10-04

Family

ID=22707882

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002404060A Abandoned CA2404060A1 (fr) 2000-03-24 2001-03-21 Methodes de traitement de la neoplasie avec des adenovirus specifiques des cellules cibles associes a la chimiotherapie et a la radiotherapie

Country Status (5)

Country Link
EP (1) EP1318839A2 (fr)
JP (1) JP2003532638A (fr)
AU (2) AU2001243704B2 (fr)
CA (1) CA2404060A1 (fr)
WO (1) WO2001072341A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4764801A (en) * 2000-03-24 2001-10-08 Calydon Inc Cell-specific adenovirus vectors comprising an internal ribosome entry site
EP1377672A2 (fr) 2001-02-23 2004-01-07 Novartis AG Constructions de vecteurs
WO2004042025A2 (fr) 2002-11-01 2004-05-21 Cell Genesys, Inc. Vecteur d'adenovirus specifique des cellules comprenant un promoteur specifique de ebv
US20050136035A1 (en) * 2003-06-03 2005-06-23 Derek Ko Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
ES2292271B1 (es) * 2004-05-20 2009-02-16 Proyecto De Biomedicina Cima, S.L. Un vector hibrido adenovirus-alfavirus para la administracion eficaz y expresion de genes terapeuticos en celulas tumorales.
EP1900749A1 (fr) * 2006-09-12 2008-03-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Acide nucléique pour l'expression d'un polynucléotide d'interêt dans des cellules cancéreuses de mammiferès
US10173074B2 (en) * 2012-10-24 2019-01-08 The Regents Of The University Of Michigan Cancer stem cell vaccination and treatment
CN112980884A (zh) * 2021-03-03 2021-06-18 北京中因科技有限公司 一种提高腺相关病毒感染细胞感染效率的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6638762B1 (en) * 1994-11-28 2003-10-28 Genetic Therapy, Inc. Tissue-vectors specific replication and gene expression
US20020051767A1 (en) * 1995-09-13 2002-05-02 Yawen L. Chiang Cancer treatment
AU744725B2 (en) * 1997-03-03 2002-02-28 Cold Genesys, Inc. Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same
WO1998039467A2 (fr) * 1997-03-03 1998-09-11 Calydon, Inc. Vecteurs d'adenovirus specifiques de cellules exprimant l'antigene carcino-embrionnaire et leurs methodes d'utilisation
US20010006633A1 (en) * 1998-05-15 2001-07-05 David Kirn Adenovirus-chemotherapeutic combination for treating cancer
US6900049B2 (en) * 1998-09-10 2005-05-31 Cell Genesys, Inc. Adenovirus vectors containing cell status-specific response elements and methods of use thereof
US6495130B1 (en) * 1998-12-30 2002-12-17 Calydon, Inc. Target cell-specific adenoviral vectors containing E3 and methods of use thereof

Also Published As

Publication number Publication date
AU2001243704B2 (en) 2005-10-27
WO2001072341A3 (fr) 2003-03-20
AU4370401A (en) 2001-10-08
JP2003532638A (ja) 2003-11-05
EP1318839A2 (fr) 2003-06-18
WO2001072341A2 (fr) 2001-10-04

Similar Documents

Publication Publication Date Title
US7276233B2 (en) Methods of treating neoplasia with combinations of target cell-specific adenovirus and chemotherapy
US6692736B2 (en) Cell-specific adenovirus vectors comprising an internal ribosome entry site
CA2343135C (fr) Vecteurs d'adenovirus contenant des elements de reponse specifiques de l'etat des cellules, et procedes d'utilisation desdits vecteurs
US6495130B1 (en) Target cell-specific adenoviral vectors containing E3 and methods of use thereof
US6676935B2 (en) Tissue specific adenoviral vectors
US6432700B1 (en) Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same
AU744725B2 (en) Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same
US7048920B2 (en) Recombinant oncolytic adenovirus for human melanoma
US6254862B1 (en) Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof
US20030026792A1 (en) Adenovirus vectors specific for cells expressing carcinoembryonic antigen and methods of use thereof
US20170190752A1 (en) E1-minus adenoviruses and use thereof
KR101527213B1 (ko) 동물 세포에서 다중 내성을 역전시키기 위한 방법
WO1998039464A9 (fr) Vecteurs d'adenovirus contenant des elements heterologues regulateurs de transcription, et leur procede d'utilisation
US20090270485A1 (en) Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
AU2001247648B2 (en) Cell-specific adenovirus vectors comprising an internal ribosome entry site
US20030152553A1 (en) Compositions comprising tissue specific adenoviral vectors
EP1268761B1 (fr) Sequences de regulation transcriptionnelle d'uroplakine specifiques aux cellules urotheliales humaines, vecteurs comportant des sequences de regulation transcriptionnelle specifiques a l'uroplakine, et leur procedes d'utilisation
AU2001247648A1 (en) Cell-specific adenovirus vectors comprising an internal ribosome entry site
AU2001243704B2 (en) Methods of treating neoplasia with combinations of target cell-specific adenovirus, chemotherapy and radiation
AU2001243704A1 (en) Methods of treating neoplasia with combinations of target cell-specific adenovirus, chemotherapy and radiation
WO1999044423A1 (fr) Amplification d'un echange genique et traitement genique au moyen d'une replication regulee
CA2516652A1 (fr) Systeme pour la commande externe de la reproduction d'un virus oncolytique
US20040241857A1 (en) Tissue specific adenoviral vectors

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead